Logo image of IMUX

IMMUNIC INC (IMUX) Stock Fundamental Analysis

NASDAQ:IMUX - US4525EP1011 - Common Stock

0.82 USD
-0.05 (-5.75%)
Last: 8/29/2025, 8:00:02 PM
0.823 USD
+0 (+0.37%)
After Hours: 8/29/2025, 8:00:02 PM
Fundamental Rating

2

Taking everything into account, IMUX scores 2 out of 10 in our fundamental rating. IMUX was compared to 542 industry peers in the Biotechnology industry. While IMUX seems to be doing ok healthwise, there are quite some concerns on its profitability. IMUX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IMUX has reported negative net income.
IMUX had a negative operating cash flow in the past year.
In the past 5 years IMUX always reported negative net income.
IMUX had a negative operating cash flow in each of the past 5 years.
IMUX Yearly Net Income VS EBIT VS OCF VS FCFIMUX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

IMUX's Return On Assets of -165.78% is on the low side compared to the rest of the industry. IMUX is outperformed by 87.64% of its industry peers.
Looking at the Return On Equity, with a value of -300.30%, IMUX is doing worse than 70.85% of the companies in the same industry.
Industry RankSector Rank
ROA -165.78%
ROE -300.3%
ROIC N/A
ROA(3y)-170.85%
ROA(5y)-121.12%
ROE(3y)-324.95%
ROE(5y)-215.14%
ROIC(3y)N/A
ROIC(5y)N/A
IMUX Yearly ROA, ROE, ROICIMUX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IMUX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMUX Yearly Profit, Operating, Gross MarginsIMUX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for IMUX has been increased compared to 1 year ago.
The number of shares outstanding for IMUX has been increased compared to 5 years ago.
There is no outstanding debt for IMUX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IMUX Yearly Shares OutstandingIMUX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
IMUX Yearly Total Debt VS Total AssetsIMUX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -16.10, we must say that IMUX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -16.10, IMUX is doing worse than 81.18% of the companies in the same industry.
There is no outstanding debt for IMUX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -16.1
ROIC/WACCN/A
WACCN/A
IMUX Yearly LT Debt VS Equity VS FCFIMUX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

IMUX has a Current Ratio of 2.19. This indicates that IMUX is financially healthy and has no problem in meeting its short term obligations.
IMUX has a Current ratio of 2.19. This is in the lower half of the industry: IMUX underperforms 72.69% of its industry peers.
IMUX has a Quick Ratio of 2.19. This indicates that IMUX is financially healthy and has no problem in meeting its short term obligations.
IMUX has a Quick ratio of 2.19. This is in the lower half of the industry: IMUX underperforms 70.85% of its industry peers.
Industry RankSector Rank
Current Ratio 2.19
Quick Ratio 2.19
IMUX Yearly Current Assets VS Current LiabilitesIMUX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 37.33% over the past year.
EPS 1Y (TTM)37.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, IMUX will show a very strong growth in Earnings Per Share. The EPS will grow by 27.01% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y31.92%
EPS Next 2Y19.43%
EPS Next 3Y11.55%
EPS Next 5Y27.01%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IMUX Yearly Revenue VS EstimatesIMUX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B
IMUX Yearly EPS VS EstimatesIMUX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -200 -400 -600 -800 -1K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IMUX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IMUX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMUX Price Earnings VS Forward Price EarningsIMUX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMUX Per share dataIMUX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.43%
EPS Next 3Y11.55%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IMUX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMMUNIC INC

NASDAQ:IMUX (8/29/2025, 8:00:02 PM)

After market: 0.823 +0 (+0.37%)

0.82

-0.05 (-5.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-05 2025-11-05/bmo
Inst Owners51.89%
Inst Owner Change17.67%
Ins Owners1.31%
Ins Owner Change8.13%
Market Cap80.89M
Analysts85
Price Target7.96 (870.73%)
Short Float %10.35%
Short Ratio7.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-11.2%
Min EPS beat(2)-18.84%
Max EPS beat(2)-3.56%
EPS beat(4)0
Avg EPS beat(4)-8.5%
Min EPS beat(4)-18.84%
Max EPS beat(4)-3.56%
EPS beat(8)3
Avg EPS beat(8)-2.3%
EPS beat(12)3
Avg EPS beat(12)-12.37%
EPS beat(16)7
Avg EPS beat(16)-7.87%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-30.15%
PT rev (3m)-47.42%
EPS NQ rev (1m)0%
EPS NQ rev (3m)25%
EPS NY rev (1m)8.38%
EPS NY rev (3m)11%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.39
P/tB 2.39
EV/EBITDA N/A
EPS(TTM)-0.94
EYN/A
EPS(NY)-0.57
Fwd EYN/A
FCF(TTM)-0.92
FCFYN/A
OCF(TTM)-0.91
OCFYN/A
SpS0
BVpS0.34
TBVpS0.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -165.78%
ROE -300.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-170.85%
ROA(5y)-121.12%
ROE(3y)-324.95%
ROE(5y)-215.14%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 83.44%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.19
Quick Ratio 2.19
Altman-Z -16.1
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)211.81%
Cap/Depr(5y)217.64%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.76%
EPS Next Y31.92%
EPS Next 2Y19.43%
EPS Next 3Y11.55%
EPS Next 5Y27.01%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-12.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-32.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32.21%
OCF growth 3YN/A
OCF growth 5YN/A